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Neuroinflammation is increasingly recognised as playing an important role in several major 
psychiatric disorders. The mechanisms by which neuroinflammation influences 
neurotransmitter systems have for long been unknown. However, the kynurenine pathway, a 
source of several neuroactive metabolites, is thought to serve as a link between immune 
signalling and neuronal activity in the brain. Kynurenic acid (KYNA), an end-metabolite of 
the kynurenine pathway, is an endogenous N-methyl-D-aspartate-receptor antagonist that 
strongly regulates brain dopamine activity. Elevated brain levels of KYNA are suggested to be 
involved in the pathophysiology of psychotic disorders and cognition. The overall aim of this 
thesis is to investigate the interplay between inflammation and the kynurenine pathway. For 
this purpose, LPS is administered in doses that induce an inflammatory response in both 
animals and humans. Our findings show that dual, rather than a single, administration of LPS 
produces a robust induction of the kynurenine pathway, including increases in brain KYNA 
levels as well as increased turnover of brain serotonin and dopamine in rodents. Alterations in 
tryptophan metabolism via the kynurenine pathway in response to dual LPS administration is 
further shown to induce behavioural impairments, such as cognitive deficits and enhanced 
amphetamine-induced locomotor activity. In human primary dermal fibroblasts, IFN-γ and IL-
1β or their combination, were used to trigger the kynurenine pathway. Forty-eight hours post-
stimulation, IL-1β did not elevate extracellular kynurenine and KYNA levels, however IFN-γ 
induced an 11.5-fold increase in kynurenine and an 8-fold increase in KYNA and the 
combination of IL-1β with IFN-γ resulted in a synergistic increase in both kynurenine and 
KYNA. Kynurenine aminotransferase (KAT II) is the main enzyme involved in the synthesis 
of KYNA. Nevertheless, pharmacological inhibition of KAT II only to some extent reduced 
the cytokine-induced release of KYNA. In rodents, dual LPS administration increased brain 
KYNA levels despite pharmacological inhibition of KAT II or genetic ablation of the enzyme. 
To translate the experimental results obtained in the present thesis to humans, we investigated 
the effects of systemic LPS administration in healthy human subjects on the kynurenine 
pathway. Administration of LPS activated both the neurotoxic and the neuroprotective branch 
of the kynurenine pathway for at least 48 h post LPS-injection.  
Overall, the results of the present thesis suggest that the dual LPS model can be used as an 
animal model, showing both face and construct validity regarding increased central and 
decreased peripheral KYNA levels as well as regarding aspects of behaviour reflecting 
psychosis and cognitive deficits. In combination with a cellular assay, this model would be 
suitable for translational studies of novel immunomodulatory agents, aiming at diminishing 
KYNA synthesis in psychotic disorders. This thesis, by the means of diverse experimental 
approaches ranging from the biochemical level, animal behaviour experiments and cellular 
systems to an experimental human endotoxemia model, confirms the hypothesis of the 
immune regulation of the kynurenine pathway in psychiatric disorders. 
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1.1 THE KYNURENINE PATHWAY – PHYSIOLOGY 
The essential amino acid tryptophan, important for protein synthesis, serves as the substrate for 
generating numerous substances with crucial physiological roles. While tryptophan is the 
origin of serotonin and melatonin synthesis, the kynurenine pathway (Figure 1) is the cardinal 
biochemical pathway of tryptophan degradation, which is conserved throughout evolution 
(Ball et al., 2014) and across species. In mammals, 90-95 % of tryptophan is degraded via the 
kynurenine pathway (Leklem, 1971). The metabolites emerging from the sequential steps of 
the pathway are responsible for a variety of physiological functions, such as neuronal 
activation and immune stimulation (Adler et al., 1999; Mándi and Vécsei, 2012; Schwarcz et 
al., 2012; Stone et al., 2013; Schmidt and Schultze, 2014), as well as regulation of energy 
homeostasis (Joisten et al., 2020).  
The first and rate-limiting step of the pathway is the oxidation of tryptophan to N-
formylkynurenine by the heme-dependent enzymes indoleamine-pyrrole 2,3-dioxygenase 
(IDO1) (Hayaishi, 1976), tryptophan 2,3-dioxygenase (TDO2) (Hayaishi et al. 1957; Tanaka 
and Knox 1959; Geng and Liu 2014) and the more recently described IDO2 (Ball et al., 2009). 
N-formylkynurenine is rapidly hydrolysed by kynurenine formamidase (Gál and Sherman, 
1978) to produce the central component of the pathway, kynurenine. Further degradation of 
kynurenine can follow three possible routes. In the first, kynurenic acid (KYNA) is 
synthesized by irreversible transamination of kynurenine by kynurenine aminotransferases 
(KAT I-IV) (Han et al., 2010). In the second, kynurenine serves as a substrate for the enzyme 
kynureninase producing anthranilic acid (AA). In the third route, 3-hydroxykynurenine (3-HK) 
is formed by the enzyme kynurenine 3-monooxygenase (KMO) and subsequently, 3-
hydroxyanthranilic acid (3-HANA) by kynureninase. 3-HANA is also formed from AA 
through non-enzymatic oxidation (Baran and Schwarcz, 1990). Besides the main branch, 3-HK 
can be metabolized to xanthurenic acid (XA) by KATs (Sathyasaikumar et al., 2017) and 3-
HANA to cinnabarinic acid by non-enzymatic oxidation (Christen et al., 1992). Back in the 
third route, 3-HANA is converted by 3-hydroxyanthranilate oxygenase to 2-amino-3-
carboxymuconic semialdehyde, which non-enzymatically produces quinolinic acid (QUIN). In 
the final step, QUIN is catabolized by quinolinate phosphoribosyltransferase (QPRT) to 
nicotinamide adenine dinucleotide (NAD+) (Henderson 1949; Mehler, Yano, and May 1964), 
an important cofactor in a variety of metabolic processes. 2-amino-3-carboxymuconic 
semialdehyde can follow an alternative two-step route and is a substrate for the enzyme 2-
amino-3-carboxymuconic-6-semialdehyde decarboxylase (ACMSD) that produces the 
metabolite 2-aminomuconic-6-semialdehyde, which through a non-enzymatic reaction finally 




Figure 1. The kynurenine pathway 
 
1.2 THE KYNURENINE PATHWAY IN THE BRAIN AND PERIPHERY 
Under normal physiological conditions ~ 90 % of total tryptophan is catabolized by the 
kynurenine pathway with most of the peripheral tryptophan metabolized by the liver. Of the 
metabolites that arise from the kynurenine pathway, only tryptophan, kynurenine, and 3-HK 
can pass the blood-brain barrier (BBB) (Fukui et al., 1991), although there are studies showing 
that PIC can also enter the brain via olfactory pathways after nasal or systemic administration 
(Bergström et al., 2002). Changes in the concentrations of peripheral kynurenine pathway 
metabolites affect the kynurenine pathway in the brain, even though the underlying 
mechanisms of this apparently bidirectional communication are still unclear (Schwarcz et al., 
2012). More specifically, about 60 % of kynurenine is imported into the brain from the 
periphery (Gál and Sherman, 1978) and taken up by glial cells (Speciale and Schwarcz, 1990) 
while the rest is derived from local production in the brain. However, these data arise from 
studies investigating this pathway under physiological conditions. The regulation of the 
kynurenine pathway can be altered dramatically during immune activation or as a result of 
different pathophysiological conditions.  
All metabolites and enzymes of the kynurenine pathway are present in the brain although their 
concentration and expression levels can vary between different brain regions, cell types, and 
species as well as with age (Heyes et al., 1992; Kepplinger et al., 2005; Coggan et al., 2009). 
Based on astroglial KAT expression, KYNA production is proposed to occur in astrocytes, 
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whereas microglia express KMO, directing the pathway towards QUIN production (Guillemin, 
Kerr, Smythe, et al., 2001; Schwarcz et al., 2012) in these cells.  
 
1.2.1 Neuroactive and immune-regulatory properties of kynurenine pathway 
metabolites  
The concentrations of kynurenine pathway metabolites in the central nervous system (CNS) 
range from nanomolar to low micromolar concentrations (Schwarcz et al., 2012). Importantly 
for this thesis, several kynurenine pathway metabolites have neuroactive properties. KYNA 
binds all three ionotropic glutamate receptors, kainate-, a-amino-3-hydroxy-5-methyl-
isoxazole-4-propionate (AMPA)-, and N-methyl-D-aspartate (NMDA)-receptors (Perkins and 
Stone, 1982). At lower concentrations, KYNA binds the glycine site of the NMDA receptor 
(IC50: 8-15 µM) (Parsons et al., 1997), whereas at higher concentrations, the compound  acts as 
an orthosteric antagonist at the glutamate recognition site of the receptor (IC50: 200-500 µM) 
(Kessler et al., 1989). KYNA also acts as a reversible, competitive antagonist on AMPA and 
kainate receptors at micromolar concentrations (Kessler et al., 1989). Blockade of α7 nicotinic 
acetylcholine (α7nACh) receptors (IC50: 7 µM) by KYNA (Hilmas et al., 2001) has been 
proposed, but this mechanism remains a matter of controversy in the scientific community 
(Stone, 2020). KYNA also acts as an agonist of G protein-coupled receptor 35 (GPR35) in 
immune cells and the gastrointestinal tract (Wang et al., 2006), and of the arylhydrocarbon 
receptor (AhR), which is an intracellular protein acting as transcription factor (DiNatale et al., 
2010). Apart from receptor-mediated effects, KYNA serves as an antioxidant by binding to 
free radicals such as hydroxyl superoxide anion (Lugo-Huitrón et al., 2011). Furthermore, 
KYNA levels are age-dependent and increase with age in both rodents and humans (Erhardt et 
al., 2001; Kepplinger et al., 2005). Due to its receptor-binding profile and its ability to reduce 
glutamate receptor-mediated cytotoxicity, KYNA exerts neuroprotective effects. This can be 
physiologically relevant during epileptic episodes when elevated KYNA levels can be detected 
(Majoie et al., 2010). Furthermore, KYNA may limit tissue damage in connection to stroke or 
other brain injuries (A. Mangas et al. 2017; 2018).  
In contrast to KYNA, QUIN acts as an agonist of NMDA receptors (IC50: 180 µM) (Stone, 
1993). This, in combination with its ability to promote release and inhibit the reuptake of 
glutamate in astrocytes (Tavares et al., 2002), provides neurotoxic characteristics to the 
compound. The production and secretion of QUIN by activated microglia is increased in 
response to inflammatory stimuli in the brain (Guillemin, Smythe, et al., 2003). Also, QUIN 
induces astrogliosis and the expression of proinflammatory cytokines and chemokines in 
human primary astrocytes (Guillemin, Croitoru-Lamoury, et al., 2003; Ting et al., 2009) as 
well as gliotoxicity (Lee et al., 2010) and astrocytic apoptosis (Guillemin et al., 2005). 
Another neurotoxic mechanism of QUIN is its involvement in oxidative damage mediated by a 
complex of QUIN with iron (QUIN-Fe2+) through the formation of reactive oxygen species, 
which subsequently mediate lipid peroxidation (Goda et al., 1996; Stipek et al., 1997). 
Additionally, toxicity caused by QUIN can be due to increased production of nitric oxide 
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through activation of neuronal nitric oxide synthase and inducible nitric oxide synthase in cell 
models such as human neurons and astrocytes (Braidy et al., 2009). Studies in the rat have 
shown that the concentration and metabolism of QUIN are age-dependent (Moroni et al., 
1984; Stone and Connick, 1985).  
PIC has started to attract more attention in recent years and is proposed to balance the 
neurotoxic effects of QUIN by inhibiting the presynaptic release of glutamate (Vrooman et al., 
1993; Beninger et al., 1994). On the other hand, PIC is reported to have antiviral properties by 
inducing apoptosis of infected cells, which results in reduction of viral replication (Fernandez-
Pol et al., 2001). The anti-microbial effects of PIC are mediated by its ability to chelate metal 
ions such as Fe2+ and Zn2+ (Cai et al., 2006). The chelating property of PIC is also considered 
to activate the proinflammatory function of macrophages by inducing the expression of the 
chemokines macrophage inflammatory proteins (MIP) 1α and 1β (Bosco et al., 2000). 
Although kynurenine is the pivotal metabolite of the kynurenine pathway, little is known about 
its neuronal activity. Recent cell culture studies, though, have shown that kynurenine can 
activate the AhR. This receptor is involved in cell differentiation processes (Yamamoto et al., 
2019), tumorigenesis (Opitz et al., 2011) and immune regulation (Mezrich et al., 2010). 
 Other, less studied metabolites of the kynurenine pathway are cinnabarinic acid and XA both 
acting as agonists of different glutamate receptors (Fazio et al., 2017), with the latter also 
acting as an antioxidant by showing high efficiency in scavenging peroxyl radicals, a property 
shared with 3-HK (Christen et al., 1990). 3-HK is a metabolite raising controversies. Apart 
from anti-oxidative properties, it can also present toxic effects and more specifically, it is 
characterised broadly in the literature as an endogenous free radical generator (Colín-González 
et al., 2013). Recent studies, however, support the association of the antioxidant properties of 
3-HK with neuroprotective and anti-inflammatory effects as shown by suppression of neuronal 
death induced by cytokines in primary human fetal CNS cultures (Krause et al., 2011). 
 
1.2.2 The importance of KATs in the brain 
KYNA, the metabolite of interest in our studies, is produced by enzymatic, irreversible 
transamination of kynurenine, which is catalysed by kynurenine aminotransferases (KATs). 
This reaction consists of two steps. The KATs are involved in the first step by producing an  α-
ketoacid that is unstable and rapidly undergoes an intra-molecular cyclization leading to the 
final product KYNA (Han et al., 2010). All four mammalian KATs show transamination 
activity towards kynurenine leading to the formation of KYNA. In the CNS of mammals, four 
isoforms of KATs are identified; KAT I (also known as: glutamine transaminase K 
(GTK)/cysteine conjugate beta-lyase (CCBL) 1), KAT II (also known as: aminoadipate 
aminotransferase (AADAT), KAT III (also known as: glutamine transaminase/CCBL 2) and 
KAT IV (also known as: glutamic-oxaloacetic transaminase (GOT) 2/mitochondrial 
aspartateaminotransferase (ASAT)) (Okuno et al., 1991; Han et al., 2004, 2010). These 
isoforms have different physiological and biochemical properties, such as optimal temperature, 
pH-dependence and substrate specificity and are located in different cellular compartments. 
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All KAT isoforms are pyridoxal phosphate (PLP) dependent and form homodimers (Jansonius, 
1998). Optimum pH conditions (assessed by activity assay) are 7.5-9 for KAT I, around 7 for 
KAT II, 9-10 for KAT III and 8.5 for KAT VI (Han et al., 2010).  
KAT II is the most abundant isoform in the brain and therefore considered the most essential 
enzyme for de novo production of KYNA (Guidetti et al., 2007). Higher concentrations of 
other competing substrates do not affect KAT II activity and under physiological conditions, 
KAT II accounts for approximately 75 % of KYNA synthesis in the brain (Chang et al., 2018). 
Based on the association between abnormal KYNA levels in the CNS, psychotic symptoms 
and cognitive dysfunctions, the enzymes involved in KYNA synthesis in the brain are 
considered potential pharmacological targets for regulating brain KYNA levels (Erhardt et al. 
2009; Schwarcz and Pellicciari 2002; T W Stone and Darlington 2002; Vamos et al. 2009). 
Due to its predominant role in the human brain most studies have focused on specific 
inhibitors for KAT II. So far though, developed KAT II inhibitors have not entered clinical 
trials due to the toxicity caused by interaction with PLP (Nematollahi et al., 2016). Although 
the involvement of individual KAT isoforms in KYNA production under normal conditions 
has been studied, the respective contribution of KAT I-IV in different pathological conditions 
remains obscure. 
 
1.2.3 Interplay between the kynurenine pathway and the immune system 
The kynurenine pathway is critically regulated by the rate-limiting enzymes IDO1 and TDO2. 
Both are regulated by the immune system where cytokines can affect their expression and 
activity. TDO2 is not only subjected to corticosteroid and glucagon regulation (Campbell et 
al., 2014) but can also be induced by interleukin (IL)-1β (Urata et al., 2014; Sellgren et al., 
2016). The activity and expression of IDO1 are strongly linked to inflammatory stimuli. IDO1 
is expressed in different cells of the immune system, such as monocytes, dendritic cells, and 
macrophages (Mándi and Vécsei, 2012) and is induced by a number of cytokines such as 
interferon (IFN)-γ (Hassanain et al. 1993; Munn and Mellor 2016), IFN-α (Wichers and Maes, 
2004), IFN-β (Guillemin et al. 2001), tumor necrosis factor-α (TNF-α) (Robinson et al. 2005), 
TNF-β (Nasef et al., 2007), IL-1-α (Babcock and Carlin, 2000), IL-6 (Hayley, 2011; 
Litzenburger et al., 2014), IL-2 (Brown et al., 1989), IL-10 (Yanagawa et al., 2009), and IL-27 
(Carbotti et al., 2015). These different cytokines can induce IDO1 either alone or 
synergistically. Contrarily, IL-4 and IL-13 are implicated in the negative regulation of IDO1 
(Chaves et al., 2001). Likewise, the KMO enzyme shows an increased expression mediated by 
IL-1β and IFN-γ (Alberati-Giani et al., 1996; Zunszain et al., 2012), and upregulation of the 
mRNA for the KAT I/II is correlated with elevated cytokine levels (Kindler et al., 2020). 
Moreover, studies in human primary dermal fibroblasts show that a cytokine challenge can 
alter the profile of kynurenine pathway metabolites (Johansson et al., 2013) and induce an 
increase in transcripts encoding IDO1 after challenge with IFN-γ alone, or in combination with 
TNF-α (Asp et al., 2011). 
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While various inflammatory parameters can activate tryptophan metabolism, kynurenine 
pathway enzymes and metabolites can tune diverse aspects of the immune response. In that 
frame, IDO1 and other kynurenine pathway metabolites exert an immunosuppressive role. 3-
HANA and QUIN induce the apoptosis in T helper 1 cells (Fallarino et al., 2002). 
Furthermore, kynurenine has immunosuppressive properties via binding to AhR (Opitz et al., 
2011) and inhibits Natural Killer cells, induces T-cell death (Mándi and Vécsei, 2012) and also 
activates regulatory T cells (Treg) (Chen et al., 2008). Moreover, tryptophan depletion is used 
by host organisms against pathogen proliferation by reduction of intracellular supplies 
(Moffett and Namboodiri, 2003; Munn and Mellor, 2016). In addition, tryptophan depletion 
stunts immune reactions via an anti-proliferative and a pro-apoptotic effect on T cells (Lee et 
al., 2002). 
 
1.3 THE KYNURENINE PATHWAY - PATHOPHYSIOLOGY  
Dysregulation of the kynurenine pathway enzymes with subsequent alteration in the metabolite 
levels is related to a wide range of disorders and symptoms. The metabolism of kynurenines is 
involved in psychiatric (Erhardt et al. 2017b), neurodegenerative (Maddison and Giorgini, 
2015), inflammatory (Badawy, 2018), metabolic (Dadvar et al., 2018) and cardiovascular 
diseases (Baumgartner et al. 2019) as well as in cancer (Platten et al., 2019) and aging (Sas et 
al. 2018; Villena 2015). 
 
1.3.1 Implications of the kynurenine pathway in psychiatric disorders  
Accumulating evidence points to a dysregulation of the kynurenine pathway in psychiatric 
disorders. In subjects with schizophrenia, kynurenine and KYNA are elevated in the 
cerebrospinal fluid (CSF) (Erhardt et al., 2001; Nilsson et al., 2005; Linderholm et al., 2012) 
as well as in postmortem brain prefrontal cortex (Schwarcz et al., 2001; Sathyasaikumar et al., 
2011). Additionally, TDO2 is upregulated in postmortem brains from subjects with 
schizophrenia (Miller et al., 2004)  and bipolar patients with psychotic features (Miller et al., 
2006). In a recent meta-analysis, the association between schizophrenia and elevated levels of 
KYNA in the CNS was described (Plitman et al., 2017). Similar alterations are reported in 
bipolar patients with a history of psychosis (Olsson et al., 2012a; Lavebratt et al., 2014; 
Sellgren et al., 2016, 2019). High levels of KYNA in the CSF are also associated with acute 
psychotic symptoms in HIV-1 infected subjects (Atlas et al., 2007). In a study where primary 
dermal fibroblasts from patients with schizophrenia and bipolar disorder were cultured, it was 
shown that more KYNA and 3-HK were released in patient-derived cells compared to those 
from controls (Johansson et al., 2013). Suicidal behaviour is also linked to aberrations in the 
kynurenine pathway. Suicide attempters present with increased CSF QUIN levels and 
increased QUIN/KYNA ratio (Erhardt et al., 2013). Furthermore, reduced levels of the 
neuroprotective metabolite PIC, as well as the PIC/QUIN ratio in CSF and plasma of suicidal 




The role of the kynurenine pathway in the pathophysiology of depression is receiving 
increased attention pointing towards an imbalance between KYNA and QUIN (Ogyu et al., 
2018). Although previous studies report low levels of KYNA (Myint et al., 2007; Schwieler et 
al., 2016), it is the relative levels of KYNA to QUIN rather than the absolute concentrations of 
these metabolites that may be of importance for depression (Savitz et al., 2015). This 
hypothesis is supported by the finding of increased QUIN/KYNA ratio in plasma (Schwieler et 
al., 2016) of patients. This ratio may rise with additional episodes of depression (Savitz et al., 
2015).  
 
1.3.2 The kynurenine pathway in cognition  
Cognitive impairment is tightly connected to alterations in concentrations of kynurenine 
pathway metabolites (Solvang et al. 2019; Stone and Darlington 2013; Talarowska and 
Galecki 2015). There are both experimental and clinical studies pointing to the involvement of 
the kynurenine pathway in cognitive impairment. For instance, subjects with schizophrenia 
bearing a homozygous risk allele for a single nucleotide polymorphism (SNP) in the KMO 
gene resulting in reduced activity of KMO performed worse in a range of cognitive tests when 
compared to control counterparts (Wonodi et al., 2014). In a recent study, it was reported that 
activation of the kynurenine pathway associates with attention impairments in subjects with 
schizophrenia. Interestingly, at the same time, proinflammatory cytokines were found elevated 
in the periphery (Kindler et al., 2020). In most psychiatric and neurodegenerative disorders, 
cognitive dysfunction is a hallmark of the disease. For example, cognitive deficits are also 
prevalent in bipolar disorder (Sellgren et al. 2019; 2016) and impaired associative memory is 
related to plasma kynurenine pathway metabolites in subjects suffering from depression 
(Chirico et al., 2020). 
Indeed, elevated levels of brain KYNA are not only related to psychiatric disorders but also to 
infectious diseases such as tick-borne encephalitis (TBE) (Holtze et al., 2012),  malaria 
(Holmberg et al., 2017), and human immunodeficiency virus type 1 (HIV-1) infection (Atlas 
et al. 2007; Baran et al. 2013) as well as to neurological diseases such as Huntington's disease 
(Jauch et al., 1995) and Alzheimer’s disease (Baran et al. 1999; Chatterjee et al. 2018). Also, 
Down syndrome is associated with increased brain KYNA (Baran et al., 1996). Notably, all of 
these disorders are also associated with cognitive dysfunctions. 
The kynurenine pathway has been studied extensively with regard to cognition in animal 
models. Pharmacological inhibition of KMO or genetic ablation of this enzyme in rodents 
leads to an increase in brain KYNA levels resulting in impaired memory and learning 
(Pocivavsek et al., 2011), disrupted prepulse inhibition (PPI) (Erhardt et al., 2004), and 
reduced cognitive flexibility (Alexander et al., 2012). In accordance with this, genetic 
depletion or pharmacological inhibition of KAT II with subsequent decreased levels of KYNA 
improves memory deficits (Pocivavsek et al. 2019; 2014; Chess et al. 2007; Akagbosu et al. 
2012) and cognitive functions in both rodents and primates (Potter et al. 2010; Kozak et al. 
2014; Chess et al. 2009; Ortega et al. 2020). 
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1.4 THE IMMUNE SYSTEM IN PSYCHIATRIC DISORDERS AND COGNITIVE 
IMPAIRMENT 
The demonstration of dysfunction in the immune system in psychiatric diseases gave birth to 
the scientific field of Neuropsychoimmunology. Epidemiological studies show that early 
childhood infections (Dalman et al., 2008; Khandaker et al., 2012; Blomström et al., 2014; 
Karlsson and Dalman, 2020), winter birth (Davies et al., 2003), as well as maternal infection 
during pregnancy are associated with a larger incidence of schizophrenia (Brown, 2012; 
Blomström et al., 2016). Clinical studies show elevated CSF levels of IL-1β in patients with 
first-episode schizophrenia (Söderlund et al., 2009) and elevated CSF levels of IL-6 in subjects 
with chronic schizophrenia (Sasayama et al. 2013; Schwieler et al. 2015). Postmortem studies 
report upregulated mRNA levels of IL-1β, IL-6, IL-8, and TNF-α in the brain of patients with 
schizophrenia (Fillman et al., 2013; Trépanier et al., 2016). In the periphery, concentrations of 
cytokines IL-6, TNF-α, soluble IL-2 receptor, and the IL-1 receptor antagonist have been 
shown to be increased in subjects with schizophrenia (Goldsmith et al. 2016). In addition, 
plasma levels of IL-18 are increased and are associated with cognitive dysfunctions in subjects 
with first-episode psychosis (Orhan et al., 2018). 
With regard to bipolar disorder, the concentration of IL-1β (Söderlund et al., 2011) is 
increased in the CSF with subjects having a history of psychosis displaying the highest levels 
(Sellgren et al. 2016). Additionally, mRNA levels of IL-1β, IL-6, and IL-8 are upregulated in 
postmortem prefrontal cortex in schizophrenia subjects (Fillman et al., 2013). Suicidality is 
also strongly connected to inflammation (Nässberger and Träskman-Bendz, 1993; Lindqvist et 
al., 2009; Erhardt et al., 2013; Brundin et al., 2015, 2017). Levels of IL-8 were significantly 
lower in suicide attempters with anxiety than in healthy controls (Janelidze et al. 2015), while 
IL-6 levels in CSF were elevated and correlated to the severity of symptoms (Lindqvist et al., 
2009). 
Although there are few studies investigating CSF cytokine levels in depression, there is a 
recent study demonstrating that higher levels of IL-1β, IL-23 and IL-33 in CSF are associated 
with increased odds of perinatal depression (Miller et al., 2019). Furthermore, increased levels 
of proinflammatory cytokines TNF-α, IL-6, and IL-1β were detected in plasma from patients 
compared to healthy controls (Dantzer et al., 2008; Dowlati et al., 2010). Notably, more than 
half of the patients undergoing treatment with IFN-α, for some cancers and viral infections, 
showed symptoms of major depression (Capuron and Miller, 2004; Raison et al., 2010). In line 
with this, anti-inflammatory treatment can ameliorate the symptoms of depression (Tyring et 
al., 2006). 
 
1.5 LPS  
Lipopolysaccharide (LPS) is a cell wall component of Gram-negative bacteria. LPS activates 
different cell types of the immune system by binding to Toll-like receptors (TLRs) (Schletter 
et al., 1995; Ulevitch and Tobias, 1995), thereby providing the molecular basis for a pattern 
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recognition response of pathogens. TLRs are type I transmembrane glycoproteins that mediate 
pattern recognition and elicit immune responses after infection or tissue damage. From the ten 
different TLR subtypes that are expressed in humans, TLR-4 is involved in signalling induced 
by LPS. 
 
1.5.1 LPS and immune activation 
LPS is widely used in animal and cell experiments to trigger an immune response. 
Upregulation of the expression of proinflammatory cytokines such as IL-1β, TNF-α, IL-6 
(Parrott et al. 2016), and IFN-γ (Dantzer, 2001) follows peripheral LPS challenge in rodents. 
Moreover, in human monocytes, IL-10 and IL-8 are increased after stimulation with LPS 
(Finney et al., 2012). 
In recent years, LPS-induced endotoxemia was introduced as a model for acute systemic 
inflammation in humans in order to elucidate the interplay between brain function and 
peripheral immune responses (Schedlowski et al., 2014). LPS is also used as a tool to study 
how systemic inflammation affects motivation (Lasselin et al., 2017) and triggers mood 
disorders (Eisenberger et al., 2010; Cho et al., 2019; Irwin et al., 2019; Kruse et al., 2019), 
pain perception (Karshikoff et al., 2015, 2016) and sickness behaviour (Henderson et al. 2017; 
Lasselin et al. 2020; Regenbogen et al. 2017; Sundelin et al. 2015). 
In healthy volunteers, a low dose of endotoxin is adequate to increase plasma levels of TNF-α 
and IL-6 and to induce depression and decrease memory functions (Reichenberg et al., 2001). 
In rodents, administration of LPS results in a sickness response characterized by reduced 
locomotor activity, decreased food intake, fever, and reduced social interaction (Dunn et al., 
2005). Sickness behaviour lasts 2-6 h after LPS administration while depressive-like 
behaviours appear within 24–28 h (O’Connor et al., 2009; Salazar et al., 2012; Walker et al., 
2013). Experimental studies show that repeated administration of LPS alters blood-brain 
barrier (BBB) permeability, in particular with regard to cytokines (Banks and Erickson, 2010) 
by altering transport systems. Consequently, repeated LPS doses induce a more significant 
inflammatory response than a single injection (Tarr et al., 2012). Thus, brain and serum 
concentrations of cytokines and chemokines are altered following repeated injections of LPS 
(Erickson and Banks, 2011). Two injections of LPS, given with an interval of 16 h, induce 
mRNA expression of IL-12 p40, a cytokine playing a central role in regulating cell-mediated 
immunity (Stalder et al., 1997).  
 
1.5.2 LPS and the kynurenine pathway 
It has been known for decades that LPS upregulates IDO1 mRNA expression, as well as 
protein expression and enzyme activity, subsequently leading to an activation of the 
kynurenine pathway (Yoshida and Hayaishi, 1978). Numerous studies have also shown that 
systemic administration of LPS activates the kynurenine pathway and elicits cognitive deficits 
(Haba et al., 2012; Ming et al., 2015; Imbeault et al., 2020), anxiety (Camara et al., 2015), and 
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depressive-like behaviour in rodents (Yirmiya, 1996; O’Connor et al., 2009; Salazar et al., 
2012). Studies using mouse primary microglia demonstrate that LPS stimulation increases 
IDO1 transcription (Connor et al., 2008; Wang et al., 2010; Hemmati et al., 2019). Similar 
studies indicated that LPS administration resulted in increased L-kynurenine production 
(Fujigaki et al., 2001, 2006), which is in agreement with findings from our laboratory showing 
that stimulation of TLR-4 induces kynurenine production in mice (Imbeault et al., 2020) and in 
human monocyte cultures (Orhan et al., 2016). Depressive-like behaviour is considered to be 
related to IDO1 activation, subsequently resulting in elevation of QUIN levels (O’Connor et 
al., 2009; Salazar et al., 2012; Walker et al., 2013; Tao et al., 2020). In line with the above-
mentioned experimental data, clinical experimental studies have shown that endotoxins, such 
as LPS, enhance release of pro-inflammatory cytokines and induce the kynurenine pathway 
subsequently leading to elevations of kynurenine metabolites in plasma (Padberg et al., 2012; 
Kruse et al., 2019). 
 
1.5.3 LPS and cognition 
Peripheral administration of LPS in animals is linked to cognitive dysfunction (Ming et al. 
2015; Czerniawski et al. 2015; Haba et al. 2012; Salazar et al. 2012; Richwine et al. 2009; 
Sparkman et al. 2006). Furthermore, LPS-induced release of pro-inflammatory cytokines 
affects neuronal function resulting in the activation of cell signalling pathways that play a role 
in long-term potentiation (LTP), glutamate release, and AMPA receptor trafficking (Albensi 
and Mattson 2000; D’Arcangelo et al. 2000; Lynch et al. 2004; O’Connor and Coogan 1999; 
Vereker et al. 2000; Tancredi et al. 2000). Given that such processes are involved in synaptic 
plasticity and neurotransmission, one can surmise that cytokines, directly or indirectly, impact 
cognition. LPS is tightly linked to alterations in metabolic pathways such as the kynurenine 
pathway (O’Connor et al., 2009; Walker et al., 2013). Notably, IDO1 knockout mice are 
protected from cognitive and memory deficits induced by LPS (Heisler and O’Connor, 2015) 
and increased KYNA levels after LPS challenge in mice are related to memory dysfunction 






Overall aim of the thesis  
To investigate the interplay between inflammation and the kynurenine pathway 
 
Specific aims: 
1) Investigate the effects of immune stimulation on kynurenine pathway metabolites 
- in mice and rats (single and dual LPS treatment)  
- in primary human fibroblast cultures (LPS and cytokine stimulation) 
- in humans (single LPS treatment) 
 
2) Investigate mouse behaviour following dual LPS treatment  
 
3) Investigate if KAT II inhibition can prevent the synthesis of KYNA following 
immune stimulation 
- in mice and rats   







3 MATERIALS AND METHODS 
3.1 ETHICAL CONSIDERATIONS 
Animal studies: 
All animal experiments are based on scientific and ethical grounds and we have placed great 
emphasis on minimizing the suffering of animals. All behavioural tests are well established 
and validated. For all animal experiments in this proposal, ethical permits are approved and 
accepted by the Ethical Committee of Northern Stockholm, Sweden (N55/14, N274/15 and 
2546-2019). All animal experiments also follow the Swedish legislations (The Animal Welfare 
Act, The Animal Welfare Ordinance and Regulations from the Swedish Board of Agriculture) 
and KI Animal Welfare Body recommendations. All studies are carried out in accordance with 
the 3Rs: Replacement, Reduction, and Refinement and Directive 2010/63/EU. 
 
Human subject studies: 
Human studies are approved by the local ethical review board in Stockholm or Uppsala, 
Sweden (2010;879-31/1) or the Institutional Review Board of the St. John of God Hospital 
(Linz) and the ethics committee of the Medical University of Vienna (Nr: 1599/2017). All 
human experiments are carried out in accordance with the Bioethics Convention (Oviedo) and 
“The code of ethics of the world medical association” (Declaration of Helsinki). Every 
individual included in the studies has received verbal and written information about the 
planned research project and potential complications before providing verbal and written 
informed consent. All samples are frozen, coded with a unique barcode, and sent to biobanks. 
We have no information regarding the identity of the included individuals. The code key 
connecting to personal data is stored separately, encrypted, and will not be used within the 





3.2 DRUGS AND CHEMICALS  
All drugs and chemicals used for the experiments that resulted in the production and collection 
of the data in this thesis are described below. All drugs were of the highest purity possible. 
Animal studies: LPS (Escherichia coli serotype O111:B4, lot # 091M4031V), D-amphetamine 
and L-kynurenine sulphate salt (all from Sigma-Aldrich), KAT II inhibitor (PF-04859989, 
Sigma-Aldrich) and isoflurane (Forene®, Abbott Scandinavia).  
Isolation, culture and stimulation of primary human fibroblasts: DMEM Glutamax (Cat. # 
61965-026), HEPES buffer (Cat. # 15630056), MEM amino acids (Cat. # 11140035), sodium 
pyruvate (Cat. # 11360039), penicillin-streptomycin (Cat. # 15140-122), fetal bovine serum 
(FBS, Cat. # 10270106) all purchased from Gibco. Upon stimulation, DMEM medium (Cat. # 
21013024) from Gibco, tryptophan (Cat. # 93659) and KAT II inhibitor (PF-04859989, Cat. # 
PZ0250) both from Sigma-Aldrich and human recombinant IFN-γ (Cat. # rcyec-hifng), and 
IL-1β (Cat. # rcyec-hil1b), both from InvivoGen, were applied to the cell cultures. 
Clinical study: LPS (Escherichia coli O113 (National Reference Bacterial Endotoxin; lot 
#94332B1, Investigational Drug Management at the National Institutes of Health, Bethesda, 
Maryland). 
Analysis with high-performance liquid chromatography (HPLC): perchloric acid (PCA) 
sodium acetate and acetonitrile, zinc acetate, methanol, sodium metabisulfite, EDTA, 
Na2EDTA, octanesulfonic acid, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid 
(HVA), 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) (Sigma-
Aldrich).  
Analysis with ultra high-performance liquid chromatography-Mass spectrometry (UPLC-
MS/MS): Normal standards: tryptophan, L-kynurenine, pyridine-2,3-dicarboxylic acid, QUIN 
and KYNA (Sigma-Aldrich). Internal standards (IS): tryptophan-d3, L-kynurenine-d4, QUIN-
d3, (Toronto Research Chemicals Canada) and KYNA-d5 (C/D/N Isotopes Inc.). Solutions for 
the mobile phases: methanol and formic acid 99 % all LC-MS grade (Chromasolve, 
Honeywell, VWR International AB, Stockholm). Solutions for sample preparations: ammonia 
solution (32 %) (VWR), ZnSO4  (Sigma-Aldrich). 
RNA extraction-qPCR: Isol-RNA lysis reagent (5PRIME), amplification grade DNase I and 
Applied Biosystem Reverse Transcription Kit (Life Technologies), SYBR Green and PCR 
Master Mix (both Applied Biosystems).  
 
3.3 ANIMAL STUDIES (Paper I-III) 
All animals used for our studies were housed at 25 °C under 40–60 % humidity, on a 12-hour 
lights on/off cycle (lights on at 06:00 am). Food and water were offered ad libitum and animal 
conditions were checked daily. All animals were monitored and weighed pre- and post-LPS 
injections. Animals showing excess signs of sickness or decreasing more than 15 % in body 
weight were excluded from the study and sacrificed. At experiment termination, animals were 
sedated with isoflurane (≈ 4 % in air) and decapitated. Brains were harvested, quickly frozen, 
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and stored at -80 °C. Blood was collected and stored overnight at 4 °C. The following day, 
serum was pipetted from the blood samples and centrifuged for 15 min (1500 x g) and the 
supernatant was transferred to a new Eppendorf tube and stored at -80 °C. 
 
3.3.1 Mice 
Animals were housed in groups of 2-7 individuals. Experiments were carried out on 2.5-5-
month old adult mice weighing between 30 and 35 g upon entering the studies. A separate 
cohort of KAT II knock out (KO) mice consisted of animals at postnatal day (P) 22. Male wild 
type (WT) C57BL6/N, FVB/N and C57BL6/J mice as well as transgenic KAT II KO mice 
(FVB/N background) used for our studies were bred at our animal facility. KAT II KO mice 
were generated as previously described (Yu et al., 2004). The reason for using KAT II KO 
mice at P 22 is that under physiological conditions, KAT II KO mice show reduced KYNA 
levels in the brain up to P 28. KYNA levels return to normal concentrations in adulthood (Yu 
et al., 2004). 
 
3.3.2 Rats 
Male Sprague Dawley rats were ordered from Charles River laboratory and housed in groups 
of five individuals at arrival. The rats acclimatized for a minimum of one week prior to the 
experiments and weighed between 200-300 g when entering the study. 
 
3.4 HUMAN STUDIES (Paper IV, V) 
The Karolinska Schizophrenia Project (KaSP) is a multidisciplinary research consortium 
investigating the pathophysiology of schizophrenia. In the frame of this project, drug-naïve, 
first-episode psychosis patients and healthy controls are recruited. The recruited subjects 
undergo a battery of psychiatric and cognitive evaluations. At the end of the testing battery, 
which is conducted for one week, CSF and blood samples, as well as skin biopsies, are 
collected. Exclusion criteria are severe somatic or neurological illness, as well as 
neurodevelopmental disorders or drug abuse. Healthy control subjects are recruited via 
advertisement and undergo the same sampling procedure. Current or previous psychiatric 
illness is excluded via an interview and their health status is assessed by their medical history, 
clinical examination, blood and urine tests as well as brain MRI. Exclusion criteria are first-
degree relatives suffering from any psychotic disorder or substance abuse, including alcohol. 
Eighteen months following recruitment, patients and healthy controls returned for a follow-up 
evaluation where the same testing and sampling procedures were repeated.  
For the needs of the study on paper IV, ten healthy subjects were recruited from the KaSP 
cohort. From those, seven were males (70 %), 21-42 years old. Another cohort of ten healthy 
male individuals (not part of KaSP), 18-40 years old, was used in paper V. All subjects in 
paper V underwent a physical examination, routine laboratory testing, and an 
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electrocardiogram. All healthy volunteers were non-smokers, free from medication, and 
without any known history of disease.  
 
3.5 SAMPLE PREPARATION  
For the different analyses the samples were prepared as follows: 
3.5.1 HPLC (Paper I-III)  
Ιn order to analyse the concentration of KYNA and kynurenine in our samples they were 
prepared as follows: We used one hemisphere of the mouse brain or the upper half of the right 
hemisphere of the rat brain. Brains were placed in threefold or fivefold (w/v) 0.4 M PCA (0.1 
% sodium metabisulfite, 0.05 % EDTA) respectively, and homogenized with a disperser 
(Ultra-Turrax®, IKA, Stauffen, Germany). The brain homogenates as well as the serum were 
centrifuged at 21000 x g for 5 min and pure PCA (70 % strength, 1/10 v/v) was added to the 
supernatant. The samples were then incubated at 4 oC for at least 30 min and centrifuged again 
(21000 x g for 5 min). Immediately, the supernatants were transferred to new tubes for 
analysis. For the analysis of dopamine, 5-HT and their metabolites, 160 µl dH2O and 20 µl 
NaOH were added to 20 µl of the supernatant prepared as described for KYNA analysis. 
 
3.5.2 LC-MS/MS (Paper IV, V) 
Cell culture supernatant (cleared by centrifugation at 20800 x g for 5 min after thawing and 
before analysis), brain extract or human EDTA-plasma, calibrator sample or Quality Control 
sample (30 µl) was mixed with 30 µl of IS (0.5 µM in 10 % ammonium hydroxide solution) 
for 15 s. 60 µl of ZnSO4 (200 nM) was added and mixed for 15 s and subsequently 30 µl of 
methanol was added and mixed for 15 s. The mixture was then centrifuged for 10 minutes at 
2841 x g at room temperature. 30 µl of the supernatant were mixed with 30 µl of formic acid 5 




3.6.1 Treatments (Paper I-III) 
Animals treated with LPS received two injections intraperitoneally (i.p.) (mice: 0.83 mg/kg + 
0.83 mg/kg, rats: 0.5 mg/kg + 0.5 mg/kg) 16 hours apart (Figure 2). Control groups followed 
the same timeline and received equivalent doses of the vehicle. Animals were sacrificed 24 
hours after the first injection (for paper I also after 48, 72 and 120 h). LPS was prepared daily 
in vehicle (sterile saline) and stored at 4 °C before injection. The KAT II inhibitor (PF-
04859989) was administered i.p. in mice (5, 10 or 50 mg/kg) 40-60 min prior to the last LPS 
or vehicle injection and in rats (10 mg/kg) 40-60 min prior to the first or both LPS injections 
(Figure 2). Animals were sacrificed 24 h after the first injection. The KAT II inhibitor was 






Figure 2. Schematic representation of the treatment protocol (paper I-III) 
Mice received L-kynurenine (20 mg/kg or 40 mg/kg) or vehicle i.p. Animals were sacrificed 2 
h after injection. L-kynurenine was prepared daily in vehicle (sterile saline) and adjusted to 
pH≈ 8.2. 
 
3.6.2 Behavioural tests  (Paper II) 
All behavioural animal experiments were performed in mice, 3-4 months old. All tests were 
performed from 08:30 to 16:00. Every animal was subjected to a minimum of two days of 
handling by the researcher performing the final test and habituated to transportation to the 
testing room. Animals were left undisturbed in the testing room for at least 30 min prior to the 
start of testing. Separate cohorts of animals were used for each test. The design and treatments 
for the different behavioural test are shown in Figure 3 below. 
 
Locomotor activity test  
In order to assess locomotor activity, we used an open-field arena where each mouse was 
placed in a square Plexiglas box (50 × 50 × 21.6 cm) within a solid, sound-dampened chamber. 
The chamber was equipped with two rows of photocells (infrared sensitive) forming a two-
layer grid over the arena and a computer registered each interruption of a photocell as one 
count. Horizontal activity, rearing activity and corner time were analysed. Mice were 
habituated for three days (one session/day, 60 min/session). LPS (0.83 mg/kg) or saline was 
given after the second habituation and another dose of LPS (0.83 mg/kg) 16h later. During the 
third session (40 h after the first treatment) general locomotor activity was assessed. 
Immediately after that, animals were injected with 5 mg/kg D-amphetamine or saline and 
locomotor activity was recorded again (additional 90 min). No signs of stereotypy were 
observed. The activity prior to the injection of D-amphetamine (last 5 min, depicted as time 0) 
was used as a baseline so as to determine the area under the curve (software GraphPad Prism). 
 
Trace fear conditioning  
A fear conditioning chamber (Med Associates Inc., St. Albans, VT, USA) was used to perform 
the trace fear conditioning test. During the training session (40 h after the first LPS or saline 
injection) mice were allowed to explore the chamber (100 s) until a tone cue (20 s, 90 dB) and 
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a foot shock (2 s, 0.5 mA) were introduced with a ‘trace’ interval of 18 s. After a 100 s inter-
trial interval, another tone-shock pairing was presented before removing the mouse (30 s after 
the last shock). After three days, freezing was recorded in the same context, without any tone 
or shock exposures in order to assess context-dependent memory. Three hours later, freezing 
was recorded again in response to a cue, by placing the mouse in the same apparatus but in a 
novel environment (a plastic floor covered the metal grid and a pyramidal shape insert changed 
the shape of the rectangular box). The cue was introduced (20 s) after exploration (100 s), 
followed by a second cue (20 s) after an inter-trial interval (120 s). Freezing, defined as the 
absence of movement (excluding respiration movements), was scored automatically by the 
software (VideoFreeze v.2.5.5.0; Med Associate) and the percentage of freezing time was used 
to score learning and memory. 
 
 







Working memory was carried out in the Y-maze (PanLab) using the continuous alternation 
paradigm. Animals were allowed to explore continuously for 5 min after being placed in one 
arm of the Y-maze. The movement was recorded from above and the calculations were as 
follows: 
Spontaneous alternations: 
 !"#$%! !" !"#$%&!#'(&) ! !""
!"!#$ !"#$%& !" !"# !"#$%!& 
− 2 
Returns in the same arm: 
!"#$%& !" !"#$!%& !" !!! !"#$ !"# ! !""
!"!#$ !"#$%& !" !"# !"#$%!& 
− 1 
Alternate arm returns: 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑙𝑡𝑒𝑟𝑛𝑎𝑡𝑒 𝑎𝑟𝑚 𝑟𝑒𝑡𝑢𝑟𝑛𝑠 𝑥 100𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑟𝑚 𝑒𝑛𝑡𝑟𝑖𝑒𝑠 − 2 
 
3.6.3 Tissue isolation and fibroblast culture (Paper IV) 
For establishing the human primary fibroblast cultures, a cutaneous biopsy was taken from the 
upper (inside) arm of participants. Tissue specimens were minced and cultured in 35 mm 
dishes under a sterile glass coverslip in DMEM Glutamax, supplemented with 10 mM HEPES, 
1X MEM amino acids, 1X sodium pyruvate, penicillin (100 U/ml) - streptomycin (100 µg/ml) 
and 20 % FBS in a humidified 37 °C, 5 % CO2 incubator. Two passages later, cells were 
frozen and stored in liquid nitrogen until further use. 
 
3.6.4 Cytokine stimulation (Paper IV) 
Following thawing and two passages, cells were seeded into 96-well plates. Once they reached 
75 % confluence, the KAT II inhibitor (PF-04859989; 500 nM) or vehicle (saline) was applied 
in serum-free DMEM medium complemented with 1mM of tryptophan, 10 mM HEPES, 1x 
sodium pyruvate and penicillin (100 U/ml) - streptomycin (100 µg/ml). Human recombinant 
IFN-γ (20 ng/ml), IL-1β (10 ng/ml) or their combination, were added to the cells an hour later. 
Cell culture studies were performed in technical triplicates. Supernatants were collected 48 h 
after cytokine stimulation and kept at -80 oC until further analysis. 
 
3.6.5 Human study  (Paper V) 
The human LPS study is a prospective, randomized, single-blinded, placebo-controlled cross-
over study. At 8:00 a.m. and after overnight fasting, intravenous catheters were inserted on 
each arm of the participants. They received saline (0.9 %) or LPS (2 ng/kg) over 5 min 
together with saline (0.9 %) (total duration 90 min [200 ml/h]) at two different days (washout 
period at least 14 days). LPS was reconstituted with sterile water and prepared according to the 
manufacturer’s recommendations before the infusion. EDTA-blood samples were collected 
before and at 15, 30, 45, 60, 90, 120, 180, 240, and 360 min as well as 24  h and 48  h after 
infusion. The samples for 24 h and 48 h were collected after overnight fasting (8:00 a.m.). 
Samples were stored at -80 °C until further analysis. During the study day, subjects rested in a 
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supine position and were monitored continuously (electrocardiogram, heart rate, non-invasive 
blood pressure, and temperature). Subjects were allowed to drink water during the study day 
and eat after completion of the 6 h blood sampling. 
 
3.7 ANALYSES  
3.7.1 HPLC (Paper I-III) 
An isocratic reversed-phase high-performance liquid chromatography (HPLC) including a 
dual-piston, high-pressure liquid delivery pump (LC-10AD VP; Shimadzu Corporation, 
Kyoto, Japan) and a C18 column (ReproSil-Pur, 4 × 100 mm; Dr. Maisch GmbH, 
Ammerbuch, Germany) were used to determine the concentration of kynurenine and KYNA. 
A mobile phase (50 mM sodium acetate, pH 6.2, 7 % acetonitrile) was pumped through the 
reversed-phase column at a flow rate of 0.5 ml/min. For KYNA, a second mobile phase (0.5 M 
zinc acetate) was delivered by a pump (P-500; Pharmacia, Uppsala, Sweden) post-columnar at 
a flow rate of 10 ml/h. Samples (50 µl) were manually injected to the loop (100 µl) of the 
injector (Rheodyne® 7725i; IDEX, Oak Harbor, WA, USA). Kynurenine (360 nm) was 
detected with a spectrometer (SPD-10A UV-VIS, Shimadzu Corporation) and KYNA 
(excitation 344 nm and emission 398 nm) was analyzed with a fluorescence detector (18 nm 
bandwidth, Jasco Ltd., Hachioji City, Japan). Detectors’ signals were analyzed using the 
Datalys Azur software (Grenoble, France). Retention times: kynurenine: 4 min, KYNA: 7 min. 
For determination of dopamine, DOPAC, HVA, 5-HIAA, and 5-HT, the mobile phase (70 mM 
sodium acetate, pH 4.1, 20 % methanol with 1.5 mM octanesulfonic acid and 0.01 mM 
Na2EDTA) was delivered by a pump (LC-20AD; Shimadzu Corporation) through a column 
(4.6 9 150 mm, ZORBAX Eclipse XDB-C18; Agilent Technologies, CA, USA) at a rate of 
0.68 ml/min. Samples (50 µl) were quantified in a high-sensitivity analytical cell (ESA 5011; 
ESA Inc., Chelmsford, MA, USA) electrochemically (sequential oxidation and reduction) 
controlled by a potentiostat (500 mV, Coulochem III; ESA Inc.). Signals from the detector 
were analysed using Clarity software (DataApex; Prague, Czech Republic). Retention times: 
dopamine: 6 min, DOPAC: 4 min, HVA: 7 min, 5-HT: 11.5 min, 5-HIAA: 5.5 min. 
 
3.7.2 UPLC-MS/MS (Paper IV, V) 
The UPLC-MS/MS system (Xevo TQ-XS triple quadrupole mass spectrometer; Waters, 
Manchester, UK) equipped with a Z-spray electrospray interface and a FTN system (Waters 
Acquity UPLC I-Class; Waters, Milford, MA), was operated in electrospray positive multiple 
reaction monitoring (MRM) mode. Conditions for the interface: detector gain 1, capillary 3.0 
kV, source 150 °C, desolvation 650 °C, gas flow rate; desolvation: 1000 l/h, cone: 150 l/h. 
Conditions for the UPLC system: column 50 °C (Acquity HSS T3; 1.8 µm, 2.1 × 150 mm; 
Waters, part #: 186003540), guard column (Vanguard HSS T3; 1.8 µm, 2.1 × 50 mm column; 
Waters, part #: 186003976), mobile phase A (0.6 % formic acid in water), mobile phase B (0.6 
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% formic acid in methanol). Flow rate: 0.3 ml/min, run time for each sample: 13 min. 
Autosampler: 4 °C.  
The software Masslynx 4.1 was used for calculating the dwell times for the MRM channels 
(data points 15-20) and the m/z for the MRM transitions (each individual analyte), along with 
optimal cone voltages and collision energies (determined by manual tuning using the 
instrument’s built-in fluidics system). Peak intensities in MRM transitions (m/z), recorded at 
previously determined retention times and optimized instrumental settings were: Tryptophan 
(206→118 and 146, 7.01 min), Tryptophan-d3 (208.1→118.8, 7 min), kynurenine (209→94 
and 146, 5.76  min), kynurenine-d4 (213→94, 5.7 min), KYNA (190.1→116 and 144, 7.99 
 min), KYNA-d5 (195→121, 7.89 min), QUIN (168.1→78 and 124, 2.94 min), QUIN-d3 
(171→81, 2.86  min), PIC (123.9→78 and 96, 2.17 min), PIC-d4 (128→82, 2.14 min). 
 
3.7.3 mRNA expression analysis (Paper III) 
Gene expression analysis was performed as previously described (Agudelo et al., 2014). In 
brief, Isol-RNA Lysis Reagent was used for extracting total RNA from brain hemispheres, 
according to manufacturer’s instructions. Subsequently, RNA was used for cDNA preparation 
with the Applied Biosystem Reverse Transcription Kit after being treated with Amplification 
Grade DNase I. To quantify the mRNA levels cDNA was mixed with SYBR Green and PCR 
Master Mix. Quantitative Real-Time PCR was performed in a ViiA 7 thermal cycler. Analysis 
of gene expression was carried out with the ΔΔCt method and relative gene expression was 
normalized to hypoxanthine phosphoribosyltransferase (HPRT) or TATA sequence binding 
protein (TBP) mRNA levels. Gene expression analyses were presented as mRNA relative to 
controls. (For primer sequences used see paper III). 
 
3.8 METHODOLOGICAL CONSIDERATIONS 
3.8.1 Behavioural tests  
Testing psychotic behaviour and especially positive symptoms of schizophrenia 
(hallucinations, delusions, disordered thoughts and speech) in animals is challenging. Few tests 
are available for rodents modelling behaviours relevant to positive symptoms. Existing tests 
are hyperactivity in response to novelty or stress (Geyer and Moghaddam, 2002; Young et al., 
2016), hyperlocomotion induced by psychostimulants (Staton and Solomon, 1984; Ikemoto, 
2002) and prepulse inhibition (PPI) (Braff and Geyer, 1990; Bakshi and Geyer, 1998; 
Swerdlow et al., 2001). In the studies presented herein, we have used the D-amphetamine-
induced hyperlocomotion paradigm. Apart from the positive symptoms, also cognitive 
impairments belong to the symptomatology of schizophrenia. Working memory is the ability 
to rapidly store and manipulate new information and distinguish it from the old. Testing 
working memory is a way to evaluate cognitive dysfunctions. Many of the behavioural models 
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Table 1. Behavioural test reported in the literature using the dual LPS model. References are for primary brain 
areas involved in the testing. *tests included in this thesis, **CSPP circuitry: limbic cortex, striatum, pallidum 
and pontine tegmentum  
A: (Oliveros et al., 2017), B: (Peyton et al., 2019), 1: (Heindorf et al., 2018; Darmohray et al., 2019), 2: 
(McEwen et al., 2016), 3: (Richman et al., 1986; Zahrt et al., 1997; Hughes, 2004; Bach et al., 2008), 4: 
(Spieker et al., 2012; Kim et al., 2018), 5: (Staton and Solomon, 1984; Ikemoto, 2002), 6:(Maren, 2008), 7: 




Tests, such as trace fear conditioning and Y-maze (used for producing the results included in 
this thesis), are characterised by high face validity (Geyer and Moghaddam, 2002; Jones et al., 
2011). To model the negative features of schizophrenia, the third and last cluster of the 
disease’s symptoms, researchers use paradigms that evaluate anxiety features. The test used 
here, evaluated time spent in the center of an open-field. In Table 1, all behavioural tests 
reported in the literature using the dual LPS model are summarized. 
Together, the behavioural results suggest an effect on cognitive processes, more specifically 
long-term (reference) memory and/or memory recall and on psychosis-like behaviours related 
to increased striatal dopamine. However, given the literature findings regarding alterations in 
kynurenine pathway metabolites and enzyme expression in the prefrontal cortex, the testing 
battery could be expanded to include more specific tests of this brain region including tests of 
executive function and attention.  
	
Locomotor activity test  
The locomotor activity test is broadly used in animal behaviour studies to set the baseline 
level of motor activity, but also for detecting changes in locomotion used for validating 
models of schizophrenia and effects of antipsychotic treatments (Geyer and Moghaddam, 
2002). Drug-induced hyperlocomotion is characterized by construct and face validity. 
Construct validity is defined by common features in neuropharmacological mechanisms 
among humans and rodents with different behavioural outcome. On the contrary, face 
validity is based on the fact that psychomotor agitation - a symptom in schizophrenia - is 
common between humans and rodents (Powell et al., 2009). The concept of using locomotor 
hyperactivity for testing psychotic-like behaviour is based on the principle that induced 
dopaminergic activity in rodents results in motoric hyperactivity, which includes increased 
forward and/or horizontal locomotion, vertical activity or rearing and - in higher doses - 
stereotypy (Van Den Buuse, 2010). Additionally, clinical data support the concept of 
amphetamine-induced locomotion, showing that patients with schizophrenia are more 
sensitive to the effects of amphetamine, such as exaggerated stimulation of dopaminergic 
transmission (Laruelle et al., 1996; Laruelle and Abi-Dargham, 1999; Perry et al., 2009). 
The locomotor activity and specifically hypersensitivity to amphetamine has been used in 
our group to validate the effects of increased KYNA levels in rodent brain (Olsson et al., 
2012b; Liu et al., 2014).  
 
Trace fear conditioning  
Fear conditioning is a behaviour highly conserved in many animal species including rodents 
as well as humans. Rodents have a species-specific response to fear that is called freezing 
and involves complete immobility excluding breathing. Fear conditioning is used for 
assessing memory and learning (Kim and Fanselow, 1992). It consists of a single learning 
session (conditioning), which causes behavioural changes that are robust and long lasting. 
The term fear conditioning covers two separate assays, cued and contextual fear conditioning 
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that are focusing on different neural processes. Cued fear conditioning is a type of Pavlovian 
conditioning that consists of an associative learning task in which mice learn to associate a 
neutral cue-tone stimulus with an aversive stimulus, a mild electrical foot shock. With 
context fear conditioning, we are assessing memory formation and recall, since animals learn 
to associate the shock with the training context such as the cage characteristics. The brain 
region that is involved in the acquisition and expression of conditional fear is the amygdala, 
while the hippocampus is involved in contextual fear conditioning. Both single and dual LPS 
administrations are connected with learning and memory deficits. A single LPS dose is 
linked to disruptions in contextual fear conditioning (Terrando et al., 2010; Imbeault et al., 
2020) and repeated LPS administration to impaired Pavlovian conditioning (Oliveros et al., 
2017) and reference memory (Peyton et al., 2019). Trace fear conditioning in our studies 
was implemented in the same way as in previous studies from our and other groups 
(Terrando et al., 2010; Liu et al., 2014; Imbeault et al., 2020). 
 
Y-maze  
The Y-maze test is based on spontaneous alternation behaviour, a process assessing spatial 
learning and working memory, and is built on the explorative and curious nature of rodents 
(Deacon and Rawlins, 2006). The parts of the brain that are involved in the testing are 
mainly the hippocampus, the prefrontal cortex and the striatal circuits. The test is performed 
in a Y-shaped maze consisting of three identical arms having a 120° angle between them. 
Animals tested have free access to all three arms after entering the center of the maze. 
Rodents typically prefer to explore a new arm of the maze rather than re-entering the one 
already visited. Remembering which arm was just entered utilizes working memory. Mice 
with learning and memory deficits show lower spontaneous alternation behaviour (entries 
between arms) as a result of reduced ability to distinguish among previously seen and novel 
objects (Dudchenko, 2004).  
 
3.8.2 Human primary fibroblasts 
Fibroblasts are primary cells that can easily be obtained from individuals using a 
minimally invasive procedure. They are stable and easy to culture. Additionally, fibroblast-
derived cell lines maintain their genetic stability for a long period, up to 15-20 passages 
(Hänzelmann et al., 2015), they exhibit similarities at the molecular level with cells coming 
from the CNS (Kálmán et al., 2016) and possess, to a high extent, signalling pathways as well 
as receptors and transcription factors similar to cells of neuronal origin (Rieske et al., 2005). 
There are several reasons why we chose human primary dermal fibroblast cultures for 
establishing a cell model to complement our animal studies. Previous studies have shown that 
disease-related alterations of the kynurenine pathway in patients with schizophrenia may be 
reflected in patient-derived skin fibroblasts (Asp et al., 2011; Johansson et al., 2013). In our 
studies, we provide further support for the use of patient-derived fibroblasts as an essential tool 
to investigate the interplay between the immune system and the kynurenine pathway by 
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elucidating the mechanisms involved in this communication. This is clinically important as 
increased knowledge on this issue may enable the development of diagnostic and prognostic 
tools. Since fibroblasts are relatively easy to obtain, they can be isolated from different groups 
of patients with various disorders, thereby potentially providing better medication for these 
patients, involving a personalized treatment approach. Skin biopsy-derived fibroblasts 
originating from a well-characterized cohort of patients, such as our KaSP project, allow cell 
biological and functional comparisons between patients and healthy controls, and the 
possibility to store patient-derived and control cells in a bio-bank for future analysis. Such a 
bio-bank would allow evaluating possible biomarkers and pharmacological targets for 
psychiatric disorders. 
Obviously, the relatively simplistic fibroblast model comes with a series of limitations. 
Most importantly, fibroblasts do not primarily represent the cell types crucially involved in 
psychiatric disorders, such as CNS neurons or glia. This obstacle can, at least in part, be 
circumvented by the establishment of induced pluripotent stem cells (iPSCs) from skin 
biopsies. Furthermore, subsequent differentiation into relevant cell types such as neurons and 
astrocytes, as well as the establishment of 3D cultures or organoids could represent 
sophisticated in vitro models for studying disease-relevant molecular mechanisms. In this way, 
potential traits of the individual patient relevant to the disease may be correlated to specific 
biological aberrations in the particular cell types studied. However, we need to keep in mind 
that the use of dermal fibroblasts alone hardly reflects a realistic situation when investigating 
the pathophysiology of multifactorial diseases such as psychiatric disorders. Such a simplistic 
cell model is rather used to investigate mechanistic aspects of a complex system and increase 
the understanding of the etiology of these disorders. 
 
3.8.3 Human LPS model 
In order to bridge our experimental findings (animal and cell culture) with human research, we 
used a well-established human in vivo model of systemic inflammation. This translational 
model of experimental human endotoxemia induced by intravenous administration of LPS 
elicits a transient, controlled, reproducible, and well-tolerated systemic inflammatory response. 
The dose used in the literature for the LPS challenge in humans ranges between 0.4 ng/kg to 4 
ng/kg. Such doses are safe and without any known long-term health risks for the participating 
subjects. During the first 2-4 h, LPS infusion is clinically characterized by increased 
temperature, chills, fatigue, myalgia, backache, headache, and nausea (flu-like symptoms), as 
well as decreased blood pressure, tachycardia, and tachypnea. In addition, LPS affects mood 





3.8.4 Chromatography methods 
HPLC is a method where the compounds are determined based on their retention time through 
a column and detected by a fluorescent, UV or electrochemical detector that measures the 
intensity of absorbance. The ultra high-performance liquid chromatography-Mass 
spectrometry (UPLC-MS/MS) method is a combination of HPLC with MS, where the different 
compounds are ionized and separated according to their mass/charge ratio by a mass analyser. 
The combination of the two analytical methods improves accuracy and sensitivity and also 
reduces experimental error.  
Traditionally, our group has used HPLC for the analysis of tryptophan, KYNA and 
kynurenine. The UPLC-MS/MS was introduced in the laboratory recently and provides the 
opportunity to analyse several kynurenine pathway metabolites simultaneously. A side-by-side 
comparison using identical samples for HPLC and UPLC-MS/MS, clearly show that the 
methods yield highly comparable data for KYNA (Figure 4).  
The selectivity, specificity, sensitivity, linearity, precision, accuracy, and matrix effect of the 
LC-MS/MS method used for measuring tryptophan and kynurenine metabolites has been 
validated by following the guidelines for bioanalytical method validation from the US FDA 
(https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-
Industry.pdf) and the EMA (https://www.ema.europa.eu/en/documents/scientific-
guideline/guideline-bioanalytical-method-validation_en.pdf) (Schwieler et al., 2020) (Trepci et 
al., 2020 in press). In brief, all metabolites measured in the present thesis (tryptophan, 
kynurenine, KYNA, QUIN) are stable for up to four freeze-thaw cycles with less than 5 % 
variation and up to 4 h on bench at room temperature with less than 10 % variation. The lowest 
level of detection (S/N ratio of three) and the lowest level of quantification (S/N ratio of ten) 
are: tryptophan (10/10 µM), kynurenine (0.1/0.25 nM), KYNA (0.1/0.5 nM), QUIN (2.5/5.0 
nM).  
 
Figure 4. Correlation of KYNA levels analyzed by LC/MS and HPLC. Samples are from the human primary 



















Spearman r = 0.9  
p = < 0.0001















Spearman r = 0.9  




3.9 DATA ANALYSIS - STATISTICS 
For papers I-IV, statistical analyses were done in Prism (GraphPad Software Inc.), and data 
are presented, as mean ± SEM. P values below 0.05 are considered statistically significant. 
Data were analyzed using one-way (paper I), or two-way ANOVA followed by post-hoc 
Bonferroni’s (papers I-III) or Sidak’s (paper IV) multiple comparisons or unpaired t-test 
(paper II, III). Grubbs’ test was used for identify outliers (paper II).  
Statistical analyses for paper V were carried out using R programming language (R version 
4.0.2). The alpha-level of significance was set at 0.05. P values below 0.005 were considered 
statistically significant. For each time point, a linear mixed-effect model was performed. Data 
were analyzed using post-hoc Bonferroni’s correction. A linear mixed-effect model was also 





4.1 MODELS OF INFLAMMATION  
The overall scope of the studies included in this thesis was to investigate the interplay between 
inflammation and the kynurenine pathway. For that purpose, LPS was used in doses that 
induce a low-grade inflammatory response for both animals and humans, adjusted to the needs 
of each study. For our cell model, we used a cytokine model known to induce the kynurenine 
pathway.  
 
4.1.1 LPS administration in rodents (Paper I-III) 
Experimental inflammation in response to administration of LPS results in behavioural 
changes lasting long after the sickness behaviour has passed. As described above, single 
administration of LPS induces depressive-like behaviour through activation of the kynurenine 
pathway and increased QUIN (O’Connor et al., 2009; Salazar et al., 2012; Walker et al., 2013; 
Tao et al., 2020). Our findings here show that dual administration of LPS provides a more 
robust induction of the kynurenine pathway and that the kynurenine pathway metabolite 
profile is altered in a different manner than by a single administration of LPS.  
 
4.1.1.1 Dual administration of LPS differentially alters brain and peripheral 
levels of kynurenine pathway metabolites (Paper I) 
The increase in KYNA observed in psychiatric disorders is associated with an increase in 
proinflammatory cytokines (Lindqvist et al., 2009; Söderlund et al., 2009, 2011; Schwieler et 
al., 2015). In order to establish an animal model recapitulating this scenario we aimed to elicit 
a systemic, low-grade inflammation in rodents. During the optimization phase of the LPS 
treatment protocol in mice, we realized that a single injection of LPS effectively induced the 
kynurenine pathway in the brain and led to increased production of the neurotoxic metabolite 
QUIN, but hardly any changes were observed in the levels of the neuroprotectant metabolite 
KYNA (Figure 5).  
In paper I, we used dual injections of LPS (0.83 mg/kg + 0.83 mg/kg, i.p.), administered 16 h 
apart. Dual injections of LPS induced the kynurenine pathway distinctly and resulted in 
increased cerebral levels of kynurenine and QUIN as well as KYNA (Figure 5A, C, E). In the 
periphery, we found increased levels of kynurenine, decreased levels of KYNA and unaffected 
levels of QUIN (Figure 5B, D, F). To control that the observed changes following dual LPS 
injections were not the result of the double amount of LPS applied, we further analysed 
kynurenine levels after injection of 1.66 mg/kg LPS. Interestingly, we found that the increase 
in brain KYNA was a consequence of repeated exposure to LPS, rather than administration of 
a higher dose (Figure 6). The protocol emerging from this study emphasizes that two injections 
of LPS induce the kynurenine pathway more efficiently than a single exposure. This finding is 
in agreement with a previous study, showing that repeated injections of LPS are required to 
elicit a pronounced inflammatory response (Erickson and Banks, 2011). Interestingly, the 
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results following dual injection of LPS reflect the situation in subjects with schizophrenia, 
where increased KYNA levels are detected in the brain (Erhardt et al., 2001; Schwarcz et al., 
2001; Nilsson et al., 2005; Sathyasaikumar et al., 2011; Linderholm et al., 2012) and 




Figure 5 Kynurenine (A, B), Kynurenic acid (KYNA, C, D) and Quinolinic acid (QUIN, E, F) levels in mouse 
brain (A, C, E) and serum (B, D, F) after single (0.83 mg/kg) or dual (2 × 0.83 mg/kg) LPS injection. Mice were 
sacrificed up to 120 h after the first injection. n = 5-8 in each group. Levels are mean ± SEM. Two-way ANOVA, 
post hoc Bonferroni. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p ≤ 0.05 versus SAL + SAL; ++++ p < 0.0001, 
+++ p < 0.001, ++ p < 0.01, + p ≤ 0.05 versus LPS + LPS; ## p < 0.01, # p ≤ 0.05 versus LPS + SAL; °°°° p < 




Figure 6. KYNA levels in mouse brain after single (0.83 mg/kg or 1.66 mg/kg) or dual (2 × 0.83 mg/kg) LPS 
injection. Mice were sacrificed 24 h after the first injection. n = 3-8 in each group. Levels are mean ± SEM. One-
way ANOVA, post hoc Bonferroni. ****p < 0.0001. 
In paper I, we also analysed monoamines and their metabolites in the brain. Dopamine and its 
metabolites HVA and DOPAC as well as serotonin (5-HT) and its metabolite 5-HIIA were 
analysed. As reflected by increased HVA:Dopamine and 5-HIAA:5-HT ratios after dual LPS 
injections (24 h and 48 h) and 24 h after a single LPS injection, we suggest that the turnover of 
dopamine and serotonin is affected by LPS (Figure 7). 
 
Figure 7. Metabolite concenration ratios in the brain: 5-HT:5-HIAA (A), DOPAC:Dopamine (B), and 
HVA:Dopamine (C) after a single (0.83 mg/kg) or dual (2 × 0.83 mg/kg) LPS injection. Mice were sacrificed up 
to 120 h after the first injection. n = 5-8 per group. Levels are mean ± SEM. Two-way ANOVA, post hoc 
Bonferroni. ****p < 0.0001, *p ≤ 0.05 versus SAL + SAL; ++++ p < 0.0001, +++ p < 0.001, ++ p < 0.01, versus 
LPS + LPS; ## p < 0.01, # p ≤ 0.05 versus LPS + SAL; °°°° p < 0.0001, °°° p < 0.001, °° p < 0.01, °p ≤ 0.05 
versus 24 h. 
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So far, only few studies have analysed monoamines concentrations in the brain following LPS 
treatment. One study measured dopamine and its metabolites using in vivo microdialysis 
showing that HVA increased after a single LPS injection (Van Heesch et al., 2014).  
 
4.1.1.2 Alterations in the kynurenine pathway in response to dual LPS 
administration lead to behavioural impairments (Paper II) 
After establishing the protocol for dual LPS administration and clarifying how this protocol 
alters the pattern of kynurenine pathway metabolites in the brain and periphery, we were 
interested in investigating the impact of an activation of the immune system by LPS on the 
behaviour of mice with emphasis on the aspects of behaviour reflecting psychotic-like 
behaviour and cognitive deficits. In order to address this question, we used amphetamine-
induced locomotor activity, trace fear conditioning and the Y-maze tests.  
We found that mice that received two LPS injections (0.83 mg/kg + 0.83 mg/kg, i.p.) were 
more sensitive to amphetamine and showed increased locomotion, compared to saline-treated 
control mice (Figure 8). These data are in line with previous studies, where rodents with 
elevated cerebral KYNA levels are hypersensitive to amphetamine (Olsson et al., 2012b; Liu 
et al., 2014; Erhardt et al., 2017a). Although amphetamine-induced hyperactivity is used as a 
model for psychiatric disorders, it was only recently that researchers used it in humans in a 
reverse-translational approach to show similarities between humans and rodents by 
quantification of specific locomotor and exploration profiles (Young et al., 2016). Additionally 
our results are supported by positron emission tomography (PET) studies revealing that 
patients suffering from schizophrenia present an exaggerated response of the dopamine system 
after exposure to amphetamine (Laruelle et al., 1996; Laruelle and Abi-Dargham, 1999; Perry 
et al., 2009).  
For fear conditioning, decreases in both contextual and cue-dependent freezing time were 
observed following dual LPS injections (0.83 mg/kg + 0.83 mg/kg, i.p.), which is in agreement 
with results from previous studies presenting learning and memory deficits induced by a single 
LPS injection (Pugh et al., 1998; Imbeault et al., 2020) as well as with studies showing that 
dual administration of LPS induces impairments in learning (Oliveros et al., 2017; Peyton et 
al., 2019). In the Y-maze test, we did not observe any significant changes for dual LPS treated 
mice in percent of spontaneous alternation, same arm returns or alternate arm returns, but a 
reduction in total arm entries (Figure 9). These results, in combination with a reduced 
locomotor activity observed in dual LPS treated mice during the habituation phase in the open 
field, indicate either an effect on general locomotion or are related to anxiety and/or reduced 
motivation for exploration. Although these latter behaviours were related to an LPS-induced 
depression model reported previously (Remus and Dantzer, 2016), they are also in line with 




Figure 8 Dual-LPS-treated mice show increased motility in response to D-amphetamine. Area under the curve 
(AUC) was measured in response to D-amphetamine administration for A) Locomotion, B) Horizontal activity, C) 
vertical activity, D) central activity, and E) Peripheral activity. n=9-11 per group. *p<0.05, **p<0.01, ***p<0.001 
unpaired t- test. 
 
 
Figure 9. Performance in the Y-maze between dual-LPS-treated mice and controls. A) Percent spontaneous 
alternations, B) Percent alternate arm returns, C) Percent same arm returns, and D) number of total arm entries. 



































































































































4.1.1.3 Compensatory alterations in KAT expression in response to LPS 
(Paper III) 
So far, our investigations clearly show that dual LPS administration increases KYNA levels in 
the mouse brain and induces behavioural impairments. This raised the question: are KAT II 
KO mice protected from the LPS-induced increase in brain KYNA levels?  KAT II is the 
principal enzyme converting kynurenine to KYNA and its genetic ablation results in 
diminished ability to produce KYNA (Yu et al., 2004; Potter et al., 2010). Thus, one would 
expect that the loss of KAT II results in increased kynurenine and QUIN levels in the brain 
without an effect on cerebral KYNA levels following dual injection of LPS. 
Consistent with our first study, WT mice showed increased brain levels of KYNA following 
dual injections of LPS (0.83 mg/kg + 0.83 mg/kg, i.p.), but unexpectedly, the same effect was 
observed in KAT II KO mice in both P 22 (Figure 10A) and adult mice (Figure 10B). 
 
 
Figure 10.  Brain KYNA levels after dual saline or LPS (2 × 0.83 mg/kg, i.p.) WT and KAT II KO mice A) at P 
22 and B) in adulthood, n=3-9 per group. Data are presented as mean ± SEM and analysed with two-way 
ANOVA, post hoc Bonferroni. *p<0.05, **p<0.01, ****p<0.0001. 
 
In order to investigate the mechanisms behind these results we measured mRNA expression 
levels of the four KATs. Interestingly, dual LPS injections resulted in the upregulation of KAT 
III mRNA levels, both in KAT II KO mice and their WT controls at P 22 (Figure 11) and in 













































































Figure 11. Brain mRNA expression levels of KAT I (A), KAT II (B), KAT III (C) and KAT IV (D) mRNA 
expression in the brain of in WT and KAT II KO mice at P 22 following dual saline or LPS injections (2 × 0.83 
mg/kg, i.p.), n=6 per group. Data are presented as mean ± SEM and analysed using two-way ANOVA, post hoc 
Bonferroni. **p<0.01, ***p<0.001 ****p<0.0001. 
 
Figure 12. KAT I (A), KAT II (B), KAT III (C) and KAT IV (D) mRNA expression in the brain of adult WT and 
KAT II KO mice following dual saline or LPS injections (2 × 0.83 mg/kg, i.p), n=5-7. Data are presented as mean 
± SEM and analyzed using two-way ANOVA, post hoc Bonferroni. *p<0.05, **p<0.01. 
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In order to exclude the possibility that the increase of kynurenine per se was responsible for 
the observed effects, we administered kynurenine (20 mg/kg or 40 mg/kg, i.p.). These doses of 
kynurenine increased KYNA production without inducing KAT III expression. Therefore, we 
conclude that the expression of KAT III is directly regulated by immune activation by LPS. In 
addition to the genetic ablation of KAT II, we investigated whether a selective KAT II 
inhibitor (PF-04859989) could inhibit KYNA formation induced by dual LPS injections. Our 
results clearly show that pharmacological inhibition of KAT II can reduce but cannot prevent 
brain KYNA production induced by dual LPS administration in WT or KAT II KO mice (at P 
22 or adult age). Previous reports show that brain KYNA levels in KAT II KO mice stay low 
until P 28 but normalize in adulthood (Yu et al., 2004), suggesting that the other KAT 
isoforms compensate for the absence of KAT II (Yu et al., 2006). In particular, KAT III 
mRNA expression increased during development and reached the highest values in adulthood 
for both WT and KAT II KO mice (Yu et al., 2006). 
In paper III we report that dual LPS administration upregulates the expression of KAT III 
mRNA in both adulthood and at P 22 in WT mice and KAT II KO genotypes. Although all 
rodents share common features, we wanted to exclude the possibility that the induction of 
KAT III observed in mice after stimulation of the immune system by LPS originates from 
species-specific mechanism. Therefore, similar studies were performed in rats. In line with the 
results in mice, we found increased expression of KAT III mRNA and increased brain KYNA 
levels following dual injections of LPS (0.83 mg/kg + 0.83 mg/kg, i.p). Indeed, rat brain 
KYNA levels were maintained higher as a result of the dual LPS administration even after pre-
treatment with the selective KAT II inhibitor (PF-04859989). Taken together, we pinpoint a 
specific role of KAT III in the neo-synthesis of KYNA during states of inflammation and 
suggest that KAT III is a potential target for antipsychotic and cognitive dysfunction 
interventions. 
 
4.1.2 Cytokine Administration in Cells (Paper IV) 
Our next aim was to explore how immune stimulation affects kynurenine pathway metabolites 
in an isolated cell system. Given the data obtained from the animal studies, we were also 
interested in exploring, whether a cytokine-induced increase in KYNA, is prevented by 
applying the selective KAT II inhibitor PF-04859989 (500 nM). To perform our studies, we 
chose to work with primary human fibroblasts. Among the different peripheral tissues, human 
fibroblasts are easy to obtain, to culture under controlled conditions, and to store. Fibroblast 
cultures have been used in previous studies as a model system to study psychiatric disorders 
(Manier et al., 2000; Gassó et al., 2014; Kálmán et al., 2014; Mesdom et al., 2019), which is 







4.1.2.1 Cytokine stimulation in human primary fibroblasts (Paper IV) 
Stimulation of human primary fibroblasts with IL-1β (10 ng/ml) did not affect extracellular 
levels of KYNA while IFN-γ (20 ng/ml) strongly increased the production of KYNA. 
Interestingly, the combination of IFN-γ (20 ng/ml)/IL-1β (10 ng/ml) exerted a synergistic 
effect resulting in an even higher extracellular concentration of KYNA (Figure 13). The IC50 
value (in vitro enzymatic assay, (Kozak et al., 2014)) for PF-04859989 is in the nanomolar 
range (23 nM) for KAT II inhibition and in the micromolar range for the other KATs (KAT I: 
2.16 µM, KAT III: 10.7 µM and for KAT IV: > 50 µM. Administration of the KAT II inhibitor 
PF-04859989, in a dose high enough to effectively inhibit KAT II (500 nM), but still far below 
the IC50 values for the other KATs, decreased extracellular KYNA concentrations in both IFN-
γ (20 ng/ml)- and IFN-γ (20 ng/ml)/IL-1β (10 ng/ml)-treated cells with less than 50 % decrease 
for the latter (Figure 13). The inability of PF-04859989 to completely block the cytokine-
induced KYNA release further underlines the importance of other KAT enzymes in the 
production of KYNA during stimulation of the immune system.  
 
 
Figure 13. Extracellular KYNA levels in human, primary fibroblast cultures exposed to pro-inflammatory 
cytokines. Fibroblast cultures from healthy subjects (n=10) treated with vehicle, IL-1β (10 ng/ml), IFN-γ (20 
ng/ml), or their combination for 48 h. PF-04859989 (500nM) was given 1 h prior to cytokine treatment. 
***p<0.001 compared to the vehicle control group. #p<0.05, ##p<0.01 versus control group, +p<0.05, versus IFN-γ 
control group (two-way ANOVA, post hoc Sidak). Error bars provide standard error of the mean (SEM). 
 
Of note, stimulation of primary human fibroblasts with IFN-γ (20 ng/ml) and IL-1β (10 ng/ml) 
or the combination of both, did not have an impact on the production of QUIN (Figure 14C). 
Further, pre-treatment with the KAT II inhibitor did not have any effect on QUIN levels. 
However, stimulation with IFN-γ (20 ng/ml) and IL-1β (10 ng/ml) or the combination of IFN-γ 
(20 ng/ml)/IL-1β (10 ng/ml) reduced tryptophan levels, indicating a larger consumption of 
tryptophan when more kynurenine and KYNA are produced (Figure 14A). Extracellular levels 
of kynurenine were not affected by the IL-1β treatment alone, but were increased by the IFN-γ 































Administration of the KAT II inhibitor did not affect the basal or the cytokine-induced 
kynurenine levels (Figure 14B), which is in line with the relative position of KAT II in the 
pathway downstream of kynurenine. 
 
 
Figure 14. Extracellular levels of A) Tryptophan (Trp) B) kynurenine, C) QUIN in human, primary fibroblast 
cultures exposed to pro-inflammatory cytokines. Fibroblast cultures from healthy subjects (n=10) were treated 
with vehicle, IL-1β (10 ng/ml), IFN-γ (20 ng/ml), or their combination for 48 h. PF-04859989 (500nM) was given 
1 h prior to cytokine treatment. *p<0.05, ***p<0.001 versus vehicle control group, ##p<0.01, ###p<0.01 versus PF-
04859989 treated control group, +p<0.05, versus IFN-γ control group (two-way ANOVA, post hoc Sidak). Error 
bars provide standard error of the mean (SEM). 
 
In agreement with the main topic of this thesis, we also used LPS as a pro-inflammatory cue 
for the stimulation of human primary fibroblasts. Much to our surprise, neither single nor 
double stimulation at various doses (10, 20, 40, 200 ng/ml) of LPS elicited any change in 
extracellular KYNA levels. Obviously, fibroblasts are not bona fide immune cells and – even 
though they express TLR4 and react to LPS stimulation (Yao et al., 2015; Bhattacharyya et al., 
















































































responses in different cell types. In summary, inhibition of KAT II reduced the cytokine-
induced production of KYNA by approximately 40 % in human fibroblasts, suggesting that the 
increase in KYNA production following cytokine exposure highly depends on KATs other 
than KAT II.  
 
4.1.3 LPS Administration In Humans (Paper V) 
The translational model of experimental human endotoxemia induced by intravenous 
administration of LPS elicits a transient, controlled, reproducible, and well-tolerated systemic 
inflammatory response. Systemic intravenous administration of LPS (2 ng/kg) evokes a 
transient inflammatory response (Heinzl et al., 2020) and is associated with activation of both 
the neurotoxic and the neuroprotective branch of the kynurenine pathway. The present results 
show that administration of LPS (2 ng/kg) increased the ratios of tryptophan/ kynurenine, 
KYNA/ kynurenine and QUIN/ kynurenine (Figure 15) indicating activation of KMO, 




Figure 15. Ratios of metabolite concentrations after LPS (red) or placebo (blue) injection. The red line indicates 
the timepoint of LPS injection injection, the black lines the change between the three consecutive days. Data is 
presented as mean and standard error of the mean. *p<0.005.  
 
Even though the results from this study are not sufficient to conclude direct causality, the 





CRP, support the importance of the inflammatory response as an activator of the kynurenine 
pathway (Figure 16).  
 
 
Figure 16. Correlation between the maximum increase in CRP and the maximum increase in the 
kynurenine/tryptophan ratio independent of time. The black line indicates the conditional mean, the grey area 
indicates the 95 % confidence interval. 
 
The aim of the present study was to investigate whether acute, intravenous LPS administration, 
given in a dose (2 ng/kg body weight, Escherichia coli O113) evoking a substantial 
inflammatory response (Heinzl et al., 2019) affects the plasma concentration of kynurenine 
metabolites in healthy human subjects. This dose was found to increase the 
kynurenine/tryptophan ratio and showed that the pathway is active for at least 48 h post LPS-
injection. The lack of increase in specific kynurenine pathway metabolite concentrations is in 
contrast to a recent study showing that LPS (0.8 ng/kg body weight, Escherichia coli group 
O:113) increases plasma kynurenine and KYNA 2 h and 6 h, respectively, post-injection 
(Kruse et al., 2019). The reason for this discrepancy is unclear but might be related to different 
batches of LPS. It might also be related to our small sample size and the fact that we only 
included young male healthy subjects. Thus, our study might not have had the power to detect 





5 GENERAL DISCUSSION 
As a source of several neuroactive metabolites, the kynurenine pathway serves as a link 
between immune signalling and brain neurotransmission (Söderlund et al., 2011; Mándi and 
Vécsei, 2012). The present thesis, utilizing approaches ranging from biochemical analysis to 
human studies, serves to validate this link, i.e. that immune signalling can activate the 
kynurenine pathway and lead to the manifestation of aberrant behaviours also seen in 
psychiatric diseases. Most importantly, dual administration of LPS in rodents recapitulates 
many biochemical and behavioural features related to human psychotic disorders and cognitive 
dysfunctions and further emphasizes the importance of immune components in their 
pathology. We show that dual but not single administration of LPS increases KYNA levels in 
the brain while peripheral levels of the compound are decreased. Furthermore, our data show 
that dual LPS administration increases cerebral tryptophan, as well as the turnover of serotonin 
and dopamine. The finding that peripheral levels of KYNA are decreased while brain KYNA 
and dopamine turnover are increased is interesting with regard to psychotic disorders. 
Although the discrepancy between immune-induced effects on KYNA levels in the CSF 
versus peripheral tissues remains obscure, KYNA levels in serum seem to be lower (Myint et 
al., 2011; Wurfel et al., 2017), while brain levels of KYNA are higher in subjects with 
schizophrenia (Erhardt et al., 2001; Schwarcz et al., 2001; Nilsson et al., 2005; Linderholm 
et al., 2012) compared to healthy controls.   
Interestingly, animal models of psychotic disorders show increased sensitivity to 
amphetamine (see Young et al., 2016). Indeed, enhanced sensitivity to amphetamine is also 
seen in animal models where cerebral KYNA is elevated (Olsson et al., 2012b; Liu et al., 
2014; Erhardt et al., 2017a). These findings are also supported by human data, where several 
studies have shown that subjects with schizophrenia are more sensitive to amphetamine than 
healthy subjects (Laruelle et al., 1996; Laruelle and Abi-Dargham, 1999; Perry et al., 2009). In 
line with these data, and in accordance with the increased turnover of dopamine found in 
paper I, we report in paper II that dual LPS-treated mice are more sensitive to amphetamine-
induced hyperlocomotion. Although the findings of reduced spontaneous movements, as well 
as the reduced total arm entries in the Y-maze, could be a result of locomotor issues, they 
might also indicate anxiety and/or a reduced motivation to explore in dual LPS treated mice. 
Moreover, in line with our previous studies on behaviour following dual LPS treatment 
(Oliveros et al., 2017; Peyton et al., 2019), we also found cognitive deficits associated with 
learning in these mice. Therefore we conclude that dual LPS treatment in mice produces a 
robust induction of the kynurenine pathway, including an increase in KYNA levels in the 
brain. LPS-induced activation of the immune system causes cognitive deficits and enhances 
dopaminergic signalling, both of which are important hallmarks of schizophrenia and 
psychosis. Thus, the dual LPS model shows both face and construct validity as it adds 
biochemical and behavioural aspects indicative of psychotic disorders. In paper III, we 
aimed to investigate whether ablation of KAT II, either by using KAT II KO mice or by 
administration of a specific KAT II inhibitor, can protect from LPS-induced elevation of brain 
KYNA. Previous findings have shown that KAT II is the most important enzyme for KYNA 
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biosynthesis under physiological conditions in the mammalian brain (Schmidt et al., 1993; 
Guidetti et al., 1997). Unexpectedly, KAT II KO mice, as well as mice treated with a selective 
KAT II inhibitor, also displayed increased brain KYNA levels following dual LPS treatment. 
We then set out to investigate the mechanisms behind this increase in brain KYNA following 
dual LPS treatment. Here, mRNA expression levels of the four KAT enzymes were measured, 
and notably, only the expression of KAT III was upregulated by dual LPS injections. This 
effect was observed in both WT mice and KAT II KO mice and further confirmed in LPS-
treated rats. These results pinpoint a specific role of KAT III in the neo-synthesis of KYNA 
during states of inflammation. Therefore, we hypothesise that KAT III is a potential target for 
interventions aimed at improving cognitive dysfunctions and reducing psychotic behaviours 
during states of inflammation, and we are currently developing drug-like molecules aiming at 
specifically inhibiting this enzyme. This drug discovery program is performed in collaboration 
with the Drug Discovery platform at Science for Life Laboratory (SciLifeLab). Indeed, one of 
the aims of the cell culture studies leading up to paper IV was to establish a stable cell culture 
model for investigating the efficacy of newly developed KAT III inhibitors for reducing 
immune response-induced synthesis of KYNA. In the present thesis, primary human fibroblast 
cultures from healthy subjects were used for studying how pro-inflammatory stimulation 
affects the kynurenine pathway. Interestingly, stimulation with pro-inflammatory cytokines 
increased the production of kynurenine and KYNA, whereas the synthesis of QUIN was not 
affected. Moreover, treating human fibroblasts with a selective KAT II inhibitor reduced the 
cytokine-induced production of KYNA with only approximately 40 %. Thus, these data 
confirm our findings in rodents suggesting that enzymes other than KAT II are of importance 
for the neo-synthesis of KYNA during inflammation. To translate the experimental results 
obtained in the present thesis to humans, we investigated, in paper V, the effects of systemic 
LPS administration on the kynurenine pathway in healthy human subjects. A single 
administration of LPS was found to activate both the neurotoxic and the neuroprotective 
branch of the kynurenine pathway for at least 48 h post LPS-injection. However, whereas 
plasma concentrations of kynurenine and QUIN were elevated in the LPS-treated group, no 
effect on KYNA levels was observed.  
Overall, the results of the present thesis suggest that the dual LPS model can be used as an 
animal model for psychosis and cognitive deficits. The model shows face and construct 
validity regarding central and peripheral KYNA levels and reflects features of psychotic 
symptoms and cognitive impairment. In this regard, the model may be important for studying 
the involvement of inflammation in such conditions and can aid in the development of new 
treatment strategies. Thus, in combination with a cellular assay, the dual LPS model would be 
suitable for translational studies of novel immunomodulatory agents, aimed at diminishing 
KYNA synthesis in psychotic disorders.  
Turning experimental findings into clinical reality may be challenging. There are numerous 
occasions where researchers did not manage to transfer protocols from preclinical studies to 
humans and there are also a lot of clinical trials that have failed to produce results expected 
from those accumulated in relevant preclinical experiments and non-primate animal models. 
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Therefore, selection of experimental human models is of utmost importance to translate 
hypotheses into man. In the present thesis, the human endotoxemia model did not exactly 
mirror the results from our experimental studies for each specific metabolite, but it indeed 
emphasized that challenging the immune system elicits essential changes in the kynurenine 
pathway. Repeated LPS administration in humans in doses resembling those for animal 
experiments, might be required to mirror the situation in schizophrenia, but may not be 
ethically defendable. Recently, new ways to further enhance immune activation by LPS have 
been tested in humans using continuous LPS administration (Kiers et al., 2017). In this model, 
a bolus dose of LPS is followed by continuous LPS infusion over several hours. This treatment 
induces a more prolonged effect with higher cytokine concentrations, more circulating 
leukocytes, and an increased duration of fever and clinical symptoms. Possibly, the continuous 
LPS infusion model may mimic the condition of the inflammation seen in schizophrenia better 
and it would be interesting to analyse kynurenine pathway metabolites in this model. Before a 
human LPS model can be used for testing the efficacy and potency of newly developed 
inhibitors of different KATs, it will be essential to further study animal behaviour in relation to 
administration of LPS in order to strengthen the link between behavioural aberrations and the 
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